Homepage Top Section2

ROP is a rare and potentially blinding resulted due to abnormal development of retinal blood vessels in premature babies. The company has presented data from a Rainbow phase

OBI-3424 is a DNA alkylating cancer therapeutic agent that targets aldo-keto reductase 1C3 (AKR1C3) overexpressing cancers. AKR1C3 overexpression has been known to be found in various treatment-resistant and

The KUBio biomanufacturing facility for BeiGene will be located in Guangzhou in the Chinese province Guangdong, where other biotech firms are setting up operations, said GE. It will

Alopecia areata is an autoimmune disease evidenced by hair loss and often linked with profound psychological consequences. The PF-06651600 is an oral JAK 3 inhibitor, while PF-06700841 is a

Keytruda is the first anti-PD-1 therapy approved in combination with chemotherapy in Europe for first-line use in patients with metastatic NSCLC. The European approval is for the first-line

Cablivi is claimed to be the first therapeutic specifically developed to treat aTTP, a rare blood-clotting disorder. The approval was based on data from the phase II Titan

Delstrigo is a once-daily fixed-dose combination tablet of doravirine (100mg), lamivudine (3TC, 300mg) and tenofovir disoproxil fumarate (TDF, 300mg). Pifeltro (doravirine, 100mg) is a new non-nucleoside reverse transcriptase

KaNDy is focused on optimizing the potential of NT-814 as a non-hormonal treatment for common, chronic debilitating female sex-hormone associated conditions. The funding came from new US investor

CogniCann is one of MXC’s medical cannabis pharmaceutical products with a THC:CBD ratio specifically formulated to treat key Dementia symptoms and enhance specific cognitive functions. The approval was